A Phase I Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 25 Aug 2013
At a glance
- Drugs MVA BN HER2; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2012 Additional lead trial investigator (Olga Bandman) added as reported by ClinicalTrials.gov.
- 22 Sep 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.